SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Gilead Sciences

92

Gilead Sciences

GILD

Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.

Looking for leads, investment insights, or competitive intelligence?

CEO

John F. Milligan

CEO Title

President, Chief Executive Officer & Director

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Foster City, CA

Years on Fortune 500 List

9

Employees

9,000

Profile provided by S&P Global.
Gilead Sciences is also featured in these fortune lists
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$30,390-6.9%
Profits ($M)$13,501.0-25.4%
Assets ($M)$56,977
Total Stockholder Equity ($M)$18,887
Market Value — as of March 31, 2017 ($M)$88,788
Profit Ratios
Profit as % of Revenues44.4%
Profits as % of Assets23.7%
Profits as % of Stockholder Equity71.5%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)9.94
EPS % Change (from 2015)-16.5%
EPS % Change (5 year annual rate)41.1%
EPS % Change (10 year annual rate)-
Total Return
Total Return to Investors (2016)-27.6%
Total Return to Investors (5 year, annualized)29.4%
Total Return to Investors (10 year, annualized)16.4%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

Valeant's New CEO Joe Papa Has a $17 Billion Ultimatum

If he pulls it off, he will make more than all of his peers combined.

Read More →
Gilead Just Paid $125 Million to Nab a Big Market Advantage

The biotech giant can now speed up the drug review process.

Read More →
The Best Stocks to Own If Trump Brings Foreign Cash Home

These tech and pharma companies could cash in on "repatriation."

Read More →